Trials / Unknown
UnknownNCT05675605
A Study of TY-1091 in Patients With Advanced Solid Tumors
A Phase I/II Study of Oral TY-1091 in Adult Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, RET-Mutation Medullary Thyroid Cancer, and Other Tumors With RET Alterations
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 248 (estimated)
- Sponsor
- TYK Medicines, Inc · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.
Detailed description
The study consists of 2 parts, a dose-escalation part (Phase 1) and an expansion part (Phase 2). Part1 will enroll participants with advanced non-resectable NSCLC, advanced non-resectable thyroid cancer and other advanced solid tumors that have progressed following standard systemic therapy, have not adequately responded to standard systemic therapy, or the participants must be intolerant to or the Investigator has determined that treatment with standard therapy is not appropriate, or there must be no accepted standard therapy for their disease. A multicenter, open-label design is adopted for part2. According to the obtained data of safety, tolerability, PK characteristics, and preliminary efficacy of TY-1091, one or two doses will be selected to conduct a dose expansion trial, which includes 3 cohorts with 20-40 subjects in each cohort.
Conditions
- RET-altered Non Small Cell Lung Cancer
- Medullary Thyroid Cancer
- RET-altered Papillary Thyroid Cancer
- Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TY-1091 | TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg |
Timeline
- Start date
- 2023-04-24
- Primary completion
- 2025-06-01
- Completion
- 2025-12-01
- First posted
- 2023-01-09
- Last updated
- 2024-01-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05675605. Inclusion in this directory is not an endorsement.